INTERACTION OF PLATINUM-BASED CYTOSTATICS AND PLATINUM NANOPARTICLES WITH METALLOTHIONEIN - POTENCIAL SOURCE OF THE ANTITUMOR DRUG RESISTENCE

被引:0
|
作者
Zelnickova, Jaroslava [1 ]
Nejdl, Lukas [1 ,2 ]
Richtera, Lukas [1 ,2 ]
Kopel, Pavel [1 ,2 ]
Adam, Vojtech [1 ,2 ]
机构
[1] Mendel Univ Brno, Dept Chem & Biochem, Brno, Czech Republic
[2] Brno Univ Technol, Dept Microelect, Ctr 6, Fac Elect Engn & Commun, Brno, Czech Republic
关键词
Platinum; nanoparticle; cytostatics; fluorescence; metalloprotein; CISPLATIN;
D O I
暂无
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Platinum-based cytostatic represent a unique class of DNA-damaging antitumor agents and they are one the most frequently used drugs in oncology. Problem is that some kind of cancer is resistant against this type of cytostatics. This resistance can be potentially caused by metalloproteins such as metallothioneins. MTs belong to the group of intracellular cystine-rich, metal-binding proteins and hold a number of functions in body. One of them is detoxification of heavy metals. This ability of MTs can cause a decreased therapeutic effect of platinum-based cytostatics. In this work, the interaction between two isoforms of MTs (MT3 and MT2a) and several types of platinum cytostatics (oxaliplatin, carboplatin and cisplatin) as well as platinum nanoparticles (size of 10 and 40 nm) was examined by fluorimetric analysis using a fluorescence zinc indicator (Fluozin-3). Both, stationary fluorescence spectrometry and capillary electrophoresis with laser-induced fluorescence detection (ex - 488 nm, em - 530 nm) was used in the study.
引用
收藏
页码:505 / 510
页数:6
相关论文
共 50 条
  • [21] Nanoprecipitation of metallocages for platinum-based anticancer drug delivery
    Zheng, Yaorong
    Yue, Zhizhou
    Wang, Han
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [22] Editorial: The role of platinum-based antitumor prodrugs in medicinal inorganic chemistry
    Margiotta, Nicola
    Ravera, Mauro
    Erxleben, Andrea
    FRONTIERS IN CHEMISTRY, 2023, 11
  • [23] In vitro binding of an orally active platinum antitumor drug, JM216 to metallothionein
    Xing, BG
    Zhu, HF
    Shi, YB
    Tang, WX
    BIOMETALS, 2001, 14 (01) : 51 - 57
  • [24] In vitro binding of an orally active platinum antitumor drug, JM216 to metallothionein
    Bengang Xing
    Huifang Zhu
    Yanbo Shi
    Wenxia Tang
    Biometals, 2001, 14 : 51 - 57
  • [25] Ultra-small platinum-based coordination nanoparticles for radiotherapy
    George, Riya
    Fetiveau, Lucile
    Porcel, Erika
    Savina, Farah
    Bosson Bapaume, Charles
    Dragoe, Diana
    Brisset, Francois
    Remita, Hynd
    Lacombe, Sandrine
    Catala, Laure
    MATERIALS ADVANCES, 2023, 4 (21): : 5314 - 5323
  • [26] Radiotherapy Enhancement for Prostate Cancer Using Platinum-Based Nanoparticles
    Cifter, G.
    Sajo, E.
    Makrigiorgos, G.
    Ngwa, W.
    MEDICAL PHYSICS, 2013, 40 (06)
  • [27] Nanoscale coordination polymers for platinum-based anticancer drug delivery
    Rieter, William J.
    Pott, Kimberly M.
    Taylor, Kathryn M. L.
    Lin, Wenbin
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2008, 130 (35) : 11584 - +
  • [28] Synthesis of novel platinum-based nanostructures for combinatorial drug delivery
    Aryal, Santosh
    Hu, Che-Ming
    Zhang, Liangfang
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [29] An Adsorptive Transfer Technique Coupled with Brdicka Reaction to Reveal the Importance of Metallothionein in Chemotherapy with Platinum Based Cytostatics
    Krizkova, Sona
    Fabrik, Ivo
    Huska, Dalibor
    Adam, Vojtech
    Babula, Petr
    Hrabeta, Jan
    Eckschlager, Tomas
    Pochop, Pavel
    Darsova, Denisa
    Kukacka, Jiri
    Prusa, Richard
    Trnkova, Libuse
    Kizek, Rene
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2010, 11 (12): : 4826 - 4842
  • [30] Drug transporters of platinum-based anticancer agents and their clinical significance
    Burger, Herman
    Loos, Walter J.
    Eechoute, Karel
    Verweij, Jaap
    Mathijssen, Ron H. J.
    Wiemer, Erik A. C.
    DRUG RESISTANCE UPDATES, 2011, 14 (01) : 22 - 34